NCT06767436 A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer
| NCT ID | NCT06767436 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | Advanced Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-11-05 |
| Primary Completion | 2025-11-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-11-05 with a primary completion date of 2025-11-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
* Institutions will be selected * This study aims to collect real-world data, targeting patients who started treatment with Enhertu from September 2022, for clinical data collection * Among patients treated with Enhertu, those who have passed away or are no longer visiting due to hospice care will have their clinical data collected without consent until August 19, 2024 * For patients who are scheduled to receive Enhertu treatment, are currently undergoing treatment, or have previously undergone treatment but experienced disease progression and are now receiving subsequent chemotherapy (i.e., patients with newly added data after registration) * Efficacy evaluation
Eligibility Criteria
Inclusion Criteria: * Patients aged 19 years or older. * Patients with pathologically confirmed metastatic, recurrent, or unresectable gastric/gastroesophageal adenocarcinoma. * Patients whose tumor tissue shows HER2 immunohistochemistry (IHC) results of 3+ or 2+ with in-situ hybridization (ISH) positivity. * Patients who received Trastuzumab Deruxtecan as third-line or later treatment. Exclusion Criteria: * Patients with HER2-negative gastric cancer. * Patients who did not provide consent to participate in the study. * Patients who received Trastuzumab Deruxtecan as first-line or second-line treatment as part of a clinical trial.
Contact & Investigator
minkyu Jung
PRINCIPAL INVESTIGATOR
Yonsei Cencer center
Frequently Asked Questions
Who can join the NCT06767436 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Advanced Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06767436 currently recruiting?
Yes, NCT06767436 is actively recruiting participants. Contact the research team at minkjung@yuhs.ac for enrollment information.
Where is the NCT06767436 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06767436 clinical trial?
NCT06767436 is sponsored by Yonsei University. The principal investigator is minkyu Jung at Yonsei Cencer center. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.